Proactive Investors
22 Jul 2026, 06:32 UTC · 2h ago
ImmuPharma picks Thermo Fisher to manufacture diabetes drug candidate
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
22 Jul 2026, 06:32 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
ImmuPharma has appointed Thermo Fisher Scientific to develop and manufacture the finished form of its experimental diabetes treatment, Kapiglucagon. — Partnering with a major industry leader like Thermo Fisher reduces operational risk and validates the manufacturing feasibility of the drug candidate.
+0.40ImmuPharma is pursuing a 505(b)(2) regulatory pathway in the US, which may allow the company to leverage existing safety data rather than repeating full testing. — This pathway can significantly accelerate the time to market and reduce R&D costs if approved by the FDA.
+0.30The company has completed its main manufacturing partnerships for the Kapiglucagon programme after previously selecting Bachem for active ingredient production. — Completing the supply chain framework is a necessary prerequisite for moving into the clinical development phase.
+0.20Continue reading
6 related stories
Search tags
ImmuPharma is preparing an investigational new drug (IND) application to begin human testing in the United States. — The IND submission is a critical catalyst that moves a drug candidate from preclinical to clinical stages.
+0.20Which stocks this story touches
The company has appointed key manufacturing partners and secured funding to advance its diabetes treatment towards clinical development.
The company received formal government approval for a farm-out deal in Namibia, clearing a final regulatory hurdle.
The company won a competitive tender to develop and manufacture a drug for ImmuPharma.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
7h ago
